Advertisement

Topics

Companies Related to "Trial of Pemetrexed Versus Erlotinib in Pretreated Patients With Non Small Cell Lung Cancer (NSCLC)" [Most Relevant Company Matches] RSS

00:28 EST 16th February 2019 | BioPortfolio

Here are the most relevant search results for "Trial of Pemetrexed Versus Erlotinib in Pretreated Patients With Non Small Cell Lung Cancer (NSCLC)" found in our extensive corporate database of over 50,000 company records.

Showing "Trial Pemetrexed Versus Erlotinib Pretreated Patients With Small" Companies 1–25 of 5,800+

Relevant

OSI Pharmaceuticals

OSI Pharmaceuticals is committed to “shaping medicine and changing lives” by developing and commercializing high-quality and novel pharmaceutical products that extend life or improve the quality of life for patients with cancer, diabetes, and obesity. We specialize in the discovery and development of innovative molecular targeted therapies that address significant unmet medical needs, and st...


Harbor BioSciences, Inc.

Harbor BioSciences is a development-stage company with two product candidates in clinical trials: Apoptone (HE3235), in the cohort expansion portion of a Phase I/IIa trial of patients with late-stage prostate cancer, and Triolex®, in a Phase IIa trial in obese type 2 diabetes mellitus patients. Apoptone and Triolex represent the lead candidates from Harbor BioSciences' small molecule platform bas...

Biothera

Biothera, a privately held U.S. biotechnology company, is developing Imprime PGG, a late clinical stage biologic that modulates the immune response to cancer. Data from the most recent randomized phase 2 study of Imprime PGG in first line non-squamous non-small cell lung cancer (NSCLC) was featured as a late-breaking abstract in the Immunotherapy of Cancer...


Valentis

Valentis is a biotechnology company that was engaged in the development of innovative products for peripheral arterial disease (PAD), a large and unsatisfied market. On July 11, 2006 Valentis announced that no statistically significant difference was seen in the primary endpoint or any of the secondary endpoints in its Phase IIb clinical trial of VLTS 934 in PAD. The primary efficacy endpoint in t...

TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals is a privately held biotechnology company focused on the development of products for oncology and ophthalmology treatment, including agents that inhibit angiogenesis. TRACON addresses unmet needs in these areas with first-in-class product candidates that will complement existing therapies. TRC093 is a monoclonal antibody that binds to cleaved collagen to inhibit angiogenesis...

Hollis-Eden Pharmaceuticals, Inc.

Hollis-Eden Pharmaceuticals is a development-stage company with two product candidates in clinical trials: Apoptone® (HE3235), in the dose-escalation portion of a Phase I/II trial of patients with late-stage prostate cancer, and Triolex®, in a Phase IIa trial in obese type 2 diabetes mellitus patients. Apoptone® and Triolex® represent the lead candidates from Hollis-Eden's small molecule pla...

BioTechNews Denmark

TopoTarget and CuraGen Announce Initiation of NCI-sponsored Phase II Clinical Trial with PXD101 for MesotheliomaTopoTarget A/S and CuraGen Corporation announced today the initiation of patient dosing in a Phase II clinical trial evaluating the activity of PXD101, a small molecule histone deacetylase (HDAC) inhibitor, for the treatment of mesothelioma. This trial is being sponsored by the National ...

Provisio, Inc

Headquartered in Nashville, TN, Provisio, Inc. develops technologies and services that enhance clinical trial processes. Its flagship solution, iTrials, automates and streamlines the way drug trial candidates are identified, notified and enrolled. iTrials breaks the traditional paradigm associated with lengthy and costly clinical trial enrollment. Leveraging iTrials "unique-to-industry" data wareh...

Medivation, Inc.

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. In September 2008, Medivation announced a global agreement with Pfizer, Inc to develop an...

Corvus Pharmaceuticals

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of small molecule and antibody agents that target the immune system to treat patients with cancer. These agents block or modify crucial immune checkpoints and reprogram immune T cells. A Phase 1B clinical trial evaluating its oral small molecule checkpoint inhib...

Vion Pharmaceuticals

Vion Pharmaceuticals, Inc. is developing novel agents for the treatment of cancer. We have two small molecule anticancer compounds under evaluation in human clinical trials. Our product, Cloretazine® (VNP40101M) is currently being studied for the treatment of acute myelogenous leukemia (AML), including a pivotal Phase 2 trial in elderly de novo poor-risk AML. In addition a trial of Cloretazine® ...

Tricida, Inc.

Tricida, Inc. is a pharmaceutical company focused on the development and commercialization of TRC101, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with CKD. Metabolic acidosis is a condition commonly caused by CKD that is believed to accelerate the progression of kidney deterioration. Tricida has successfully...

Vicus Therapeutics, LLC

Vicus Therapeutics is a biopharmaceutical company dedicated to bringing breakthrough therapies to patients with cancer. Vicus' lead investigational therapy, VT-122, is a combination of etodolac and propranolol. VT-122 showed positive results in a Phase 2 clinical trial of lung cancer patients and is currently being evaluated in a Phase 2 clinical trial of liver cancer patients receiving Nexavar ...

Antidote Technologies Ltd

Antidote is a digital health company on a mission to accelerate the breakthroughs of new treatments by bridging the gap between medical research and the people who need it. In a world where 80% of clinical trials are delayed or closed due to lack of participants, Antidote use cutting-edge technology to match the right patients with the right trials. Antido...

Soligenix, Inc.

Soligenix, Inc. (Soligenix) is a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. Soligenix's lead product, orBec(®) (oral beclomethasone dipropionate or BDP), is a potent, locally acting corticosteroid being developed for the treatment of acute ...

Next Generation Clinical Research Consulting, Inc

Next Generation is a specialized CRO providing services to the Biotech and Pharma industries in clinical trial management and training. Our Specialties: Collaborations with smaller or emerging biotech and pharma companiesComplex projects and trial designsNovel productsAs a purposely small, niche CRO, Next Generation brings together expertise, creativity and personal service to meet your distinct...

Iinvivodata

invivodata is the worldwide leader in capturing clinical trial data of the highest integrity directly from patients. With a unique combination of scientific, technological, and regulatory expertise, invivodata has pioneered the evolution of the electronic Patient Reported Outcomes (ePRO) industry and continues to provide innovative methods that make it easy for clinical trial sponsors to attain th...

NeoMatrix, LLC

Based in Irvine, Calif., NeoMatrix© develops innovative devices that allow women and their doctors to promote optimal breast health. The company's premier product, the HALO Breast Pap Test System, is the first fully automated, noninvasive breast cancer risk assessment tool designed for use in the primary care office setting. The System has been FDA cleared for the collection of nipple aspirate fl...

Be the Partner

Be the Partner provides technology that makes clinical trials a better experience and gains patient insights beyond the trial. Our platform enables data sharing and communication between de-identified study participants and pharmaceutical companies. We partner with industry and work closely with patients and clinical research sites to better understand the...

NCRL

Founded in 1984 as the Nottingham Clinical Trial Data Centre, the Group has its origins in cardiology and statistics research in The University of Nottingham. As a commercial organisation, the Group has developed a broad range of sophisticated services and now supports clinical trial programmes ranging from small studies to international megatrials in many indications.

Callisto Pharmaceuticals, Inc.

Callisto Pharmaceuticals, Inc., is a publicly traded biotechnology company on the American Stock Exchange (AMEX:KAL) and Frankfurt Exchange (CA4). Callisto's primary focus is the clinical development of two drugs to treat cancer, L-Annamycin for relapsed leukemia and Atiprimod for relapsed multiple myeloma (MM) and bone resorption. L-Annamycin, a drug from the anthracycline family, earlier complet...

NightstaRx Limited

Nightstar is a leading retinal gene therapy company focused on developing and commercializing novel, potentially curative one-time treatments for patients suffering from rare inherited retinal diseases that would otherwise progress to blindness, and for which there are no other treatment options. Nightstar’s lead program, NSR-REP1, is being developed ...

Synergy Pharmaceuticals Inc.

Synergy Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of new drugs to treat patients with gastrointestinal (GI) diseases and disorders. Synergy’s lead drug, plecanatide, and next generation candidate, SP-333, are proprietary analogs of the natural human GI hormone, uroguanylin, and members of the new class of guanylate ...

Massive Bio, Inc.

Massive Bio provides a comprehensive precision oncology access program to patients and enterprises – including virtual tumor board, clinical trial matching, reimbursement support and data analytics services. Massive Bio’s clinical trial matching customers are Contract Research Organizations (CROs), pharmaceutical companies and diagnostics labs. M...

Trial By Fire Solutions

Trial By Fire Solutions is a global leader in web-based clinical trial management solutions and develops innovative applications to improve planning, execution and tracking of clinical studies. Since the release of its SimpleCTMS product, Trial By Fire Solutions has been providing affordable eClinical solutions to teams of all sizes.


More From BioPortfolio on "Trial of Pemetrexed Versus Erlotinib in Pretreated Patients With Non Small Cell Lung Cancer (NSCLC)"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks